SCHEMBL259498

SCHEMBL259498

CC(=O)Oc1cccc(-c2nc3nccnc3c(=O)[nH]2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.46
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
MAPT P10636 1/20 0.45
PARP1 P09874 1/20 0.42
GAPDH P04406 1/20 0.41
ADORA2A P29274 1/20 0.41
DHODH Q02127 1/20 0.41
PIN1 Q13526 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ACHE P22303 1/20 0.40
CYP3A4 P08684 1/20 0.40
GSK3B P49841 1/20 0.39
DYRK3 O43781 1/20 0.39
MAP4K4 O95819 1/20 0.39
PIM1 P11309 1/20 0.39
RPS6KB1 P23443 1/20 0.39
CSNK2A1 P68400 1/20 0.39
PKN2 Q16513 1/20 0.39
PIM3 Q86V86 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259502 0.86 ALDH1A1 (0.50) AURKAALDH1A1LMNAMAPTGAPDH
SCHEMBL259322 0.85 AURKA (0.63) AURKAALDH1A1PARP1PIN1KDM4E
SCHEMBL259621 0.85 AURKA (0.51) AURKAALDH1A1LMNAMAPT
SCHEMBL12112031 0.80 ALDH1A1 (0.43) AURKAALDH1A1LMNAMAPTGAPDH
SCHEMBL2125639 0.76 GAA (0.50) ALDH1A1PARP1PIN1KDM4EGSK3B
SCHEMBL2130092 0.76 MGAM (0.50) AURKAPARP1DHODHPIN1ACHE
SCHEMBL259479 0.76 ALDH1A1 (0.64) ALDH1A1LMNAMAPTPARP1
SCHEMBL259275 0.76 TUBB4A (0.58) ALDH1A1LMNAMAPTPARP1GAPDH
SCHEMBL259319 0.75 KDM4C (0.60) ALDH1A1LMNAMAPT
SCHEMBL259503 0.75 KDM4C (0.51) ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A AURKA 113/4885ALDH1A1 4428/4885LMNA 4331/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A AURKA 113/4885ALDH1A1 4428/4885LMNA 4331/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A AURKA 113/4885ALDH1A1 4428/4885LMNA 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.